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The Pneumonia Etiology Research for Child Health study was conducted across 7 diverse research sites and relied on standardized 
clinical and laboratory methods for the accurate and meaningful interpretation of pneumonia etiology data. Blood, respiratory 
specimens, and urine were collected from children aged 1–59 months hospitalized with severe or very severe pneumonia and com-
munity controls of the same age without severe pneumonia and were tested with an extensive array of laboratory diagnostic tests. 
A standardized testing algorithm and standard operating procedures were applied across all study sites. Site laboratories received 
uniform training, equipment, and reagents for core testing methods. Standardization was further assured by routine teleconferences, 
in-person meetings, site monitoring visits, and internal and external quality assurance testing. Targeted confirmatory testing and 
testing by specialized assays were done at a central reference laboratory.
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The primary aim of the Pneumonia Etiology Research for 
Child Health (PERCH) study was to provide a contemporary 
picture of the microbial etiology of severe pneumonia in young 
children from developing countries [1]. One of the defining 
characteristics of the study was the use of a standard case defi-
nition and a rigorous training program to achieve standard-
ization of case assessments and specimen collection [2]. The 
standardization of laboratory methods in the PERCH study 
was equally important to ensure comparability across study 
sites and for accurate and meaningful interpretation of pneu-
monia etiology results.
We have previously described the process leading to the 
PERCH diagnostic testing strategy [3–6]. Here we describe 
the laboratory methods used in PERCH and the procedures to 
ensure standardization and quality.
PERCH LABORATORY STRUCTURE
Each PERCH study site included an established research lab-
oratory with dedicated study staff overseen by 1 or more local 
laboratory managers. The PERCH laboratory director pro-
vided centralized oversight of laboratory activities across all 
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sites. To build capacity at the sites, and in alignment with the 
priorities of the Bill & Melinda Gates Foundation, all PERCH 
testing was done locally, with the exception of quality assur-
ance testing and a select subset of specialized assays, which 
were performed at the study reference laboratory (Canterbury 
Health Laboratories, Christchurch, New Zealand), which also 
served as the study specimen and isolate biorepository.
PERCH RESEARCH SITES AND LABORATORIES
The PERCH site laboratories were located in Kilifi, Kenya; 
Basse and Banjul, The Gambia; Bamako, Mali; Lusaka, 
Zambia; Soweto, South Africa; Nakhon Phanom, Sa Kaeo, and 
Nonthaburi, Thailand; and Matlab and Dhaka, Bangladesh. 
Study sites were selected through an open, global site solici-
tation and selection process. As there was little support in the 
budget to expand existing infrastructure, preference was given 
to sites with well-established research laboratories and with 
experience in pediatric pneumonia studies.
PERCH SPECIMEN COLLECTION AND TESTING 
ALGORITHM
Blood, nasopharyngeal and oropharyngeal (NP/OP) swabs, 
induced sputum (IS), and urine were collected from all PERCH 
cases at enrollment. Cases who were intubated had endotracheal 
aspirate collected in lieu of induced sputum. Gastric aspirate 
and pleural fluid specimens were collected when clinically indi-
cated. At select sites, lung aspirates (Bangladesh, The Gambia, 
Mali, South Africa) and postmortem specimens (Thailand, 
South Africa) were also collected. Among PERCH controls, 
blood, NP/OP swabs, and urine were collected at enrollment 
at all sites.
Standardized recommendations for specimen storage prior 
to laboratory evaluation were provided in standard operating 
procedures (SOPs) (Table  1). All specimens were collected 
within walking distance or within a 2-hour drive of the study 
laboratory, with the exception of Matlab, Bangladesh, where 
specimens were transported once or twice a day from the field 
hospital to the laboratory in Dhaka, and Basse, The Gambia, 
where specimens were transported 1 to 2 times weekly to the 
Fajara laboratory for molecular testing. The transportation of all 
specimens was done under controlled temperature conditions, 
as stipulated in the study SOP.
Standardized testing algorithms were developed for each 
body fluid type among cases and controls (Figure 1). Following 
testing, residual volumes of body fluid specimens were stored at 
–80°C to facilitate future research, with particular attention to 
bioethical considerations [7]. Bacterial isolates cultured in pure 
growth were stored at –80°C unless classified as contaminants.
Barcode labels were used on specimen collection containers, 
data collection forms, and laboratory requisition forms [8]. In 
the laboratory, specimen aliquots and isolates were archived in 
2-mL sterile cryovials with silicone O-rings, labeled with ther-
mostable labels, and inventoried using freezer management 
software [8]. Laboratory data were entered into an electronic 
data capture system to allow for real-time study monitoring [8].
STANDARDIZED LABORATORY METHODS
Molecular Diagnostics
To standardize molecular testing, an automated nucleic acid 
extraction platform and standardized polymerase chain reac-
tion (PCR) assays, described below, were deployed across all 
study sites. The PERCH laboratory director reviewed all PCR 
results files prior to their inclusion in the study database.
Respiratory Pathogen PCR
For PCR evaluation of respiratory specimens, we used the Fast-
track Diagnostics Respiratory Pathogens 33 multiplex PCR kit 
(FTD Resp-33 kit) (Fast-track Diagnostics, Sliema, Malta). NP/
Table 1. Specimen Transport and Storage Requirements
Specimen Transport/Storage Conditions Until
Blood culture ≤24 h, room temperature or according  
to manufacturer’s instructions
Placement in blood culture machine
Whole blood (EDTA and plain tubes) <3 days, 2°C–8°C Specimen separation
Urine ≤24 h, 2°C–8°C (≤2 h, room temperature) Freezing (–70°C)
NP/OP swabs in viral transport medium ≤8 h, 2°C–8°C (≤2 h, room temperature) Freezing (–70°C)
NP swab in STGG <8 h, 2°C–8°C Freezing (–70°C)
Induced sputum ≤24 h, 2°C–8°C (≤2 h, room temperature) Inoculation onto culture media and other primary 
laboratory processing
Lung aspirate ≤24 h, 2°C–8°C (≤2 h, room temperature) Inoculation onto culture media and other primary 
laboratory processing
Gastric aspirate ≤24 h, 2°C–8°C (≤15 min, room temperature) Tuberculosis culture
Pleural fluid ≤24 h, 2°C–8°C (≤2 h, room temperature) Inoculation onto culture media and other primary 
laboratory processing
Lung tissue ≤24 h, 2°C–8°C (≤2 h, room temperature) Inoculation onto culture media and other primary 
laboratory processing
Abbreviations: EDTA, ethylenediaminetetraacetic acid; NP/OP, nasopharyngeal/oropharyngeal; STGG, skim milk, tryptone, glucose, and glycerin.
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OP specimens were collected in viral transport medium (uni-
versal transport medium [UTM], Copan Diagnostics, Bresica, 
Italy) and refrigerated at 2°C–8°C for a maximum of 8 hours, or 
frozen at –80°C prior to nucleic acid extraction. Induced spu-
tum, pleural fluid, and lung aspirate specimens were collected 
in saline in universal containers and either refrigerated at 2°C–
8°C for a maximum of 24 hours, or frozen at –80°C prior to 
nucleic acid extraction.
Total nucleic acid extraction was performed on respira-
tory specimens using the NucliSENS easyMAG platform 
(bioMérieux, Marcy l’Etoile, France). Four hundred microliters 
of each respiratory specimen (NP specimen in UTM, induced 
sputum aliquot in normal saline, pleural fluid aliquot, or lung 
aspirate aliquot) was eluted to a final volume of 60–110  μL 
nucleic acid. Prior to extraction, induced sputum specimens 
were digested with 1:1 dithiothreitol and incubated at ambient 
temperature until any mucus was broken down.
The FTD Resp-33 kit is a real-time PCR arranged in 8 mul-
tiplex groups for the detection of the following 33 viruses, 
bacteria, and fungi: influenza A, B, and C; parainfluenza 
viruses 1, 2, 3, and 4; coronaviruses NL63, 229E, OC43, and 
HKU1; human metapneumovirus A/B; human rhinovirus; 
respiratory syncytial virus A/B; adenovirus; enterovirus, pare-
chovirus; bocavirus; cytomegalovirus; Pneumocystis jirovecii; 
Mycoplasma pneumoniae; Chlamydophila pneumoniae; 
Streptococcus pneumoniae; Haemophilus influenzae type b; 
Staphylococcus aureus; Moraxella catarrhalis; Bordetella per-
tussis; Klebsiella pneumoniae; Legionella species; Salmonella 
species; and Haemophilus influenzae species. The K. pneumo-
niae target was not used in any of the final analyses because of 
difficulties with assay specificity, as has been found elsewhere 
[9]. Positive, negative, and internal extraction controls were 
included in each run.
Quantitative PCR (qPCR) data were generated through 
the creation of standard curves using 10-fold serial dilutions 
of plasmid standards provided by FTD on an approximately 
quarterly basis at each study site, with calculation of pathogen 
density (copies/milliliter) from the sample cycle threshold (Ct) 
values. Because the results for the known standards were highly 
consistent across laboratories, standard curve data from all sites 
were pooled to create “standardized” standard curves for each 
pathogen target; data points beyond 2 standard deviations of 
the mean were excluded. Quantitative PCR was performed 
at each site using an Applied Biosystems 7500 (ABI-7500) 
Figure 1. Pneumonia Etiology Research for Child Health (PERCH) study testing algorithm. *Applies to controls as well as cases. **May include complete blood count, 
C-reactive protein, malaria, human immunodeficiency virus, CD4, and/or thalassemia testing depending on site. Abbreviations: NP, nasopharyngeal; OP, oropharyngeal; PCR, 
polymerase chain reaction; TB, tuberculosis.
Downloaded from https://academic.oup.com/cid/article-abstract/64/suppl_3/S245/3858214
by London School of Hygiene & Tropical Medicine user
on 26 January 2018
S248 • CID 2017:64 (Suppl 3) • Driscoll et al
platform (Applied Biosystems, Foster City, California). Cycling 
conditions were 50°C for 15 minutes, 95°C for 10 minutes, and 
40 cycles of 95°C for 8 seconds followed by 60°C for 34 seconds.
Pneumococcal PCR From Whole Blood Specimens
Whole blood samples were collected into a dedicated EDTA 
(ethylenediaminetetraacetic acid) tube and either refrigerated 
at 2°C–8°C for a maximum of 3 days, or frozen at –80°C prior 
to nucleic acid extraction. Total nucleic acid extraction was 
performed in batches with 200  μL of whole blood extracted 
and eluted to a final volume of 100 μL nucleic acid using the 
NucliSENS “specific B” protocol. Extracted DNA was frozen 
at –80°C until undergoing PCR for detection of the autolysin 
(lytA) gene.
Streptococcus pneumoniae nucleic acid was detected in whole 
blood using a qPCR assay based on a method from the US 
Centers for Disease Control and Prevention [10]. Mastermix 
containing 12.5  μL of Gene Expression Mastermix (Applied 
Biosystems, Life Technologies, California), 0.5  μL of each of 
the 10  μM forward and reverse primers and probe, 1  μL of 
molecular-grade water, and 10 μL of template DNA was used 
per reaction. Quantification standards consisting of lytA plas-
mids (Fast-track Diagnostics, Sliema, Malta) diluted 1:10 from 
107 copies/mL to 102 copies/mL were run in triplicate on every 
plate. A  no-template control, consisting of molecular-grade 
water, was likewise run in triplicate. Cycling conditions of 95°C 
for 10 minutes followed by 40 cycles of 95°C for 15 seconds and 
60°C for 1 minute were applied on an ABI-7500 instrument. 
Exponential amplification curves with a Ct value of <40 cycles 
were considered positive and quantified using the standard 
curve.
Confirmatory Testing of Selected PCR Targets at Reference Laboratory
All samples positive for Bordetella pertussis were tested for 
Bordetella holmesii [11]. A high proportion of samples positive 
for H. influenzae type b, especially from countries with Hib vac-
cine, called into question the specificity of that pathogen target. 
Consequently, we retested these positive samples with an estab-
lished Hib assay [12] and used the results from this second assay 
in our analyses. Due to intermittent contamination of the nucleic 
acid extraction lysis buffer with Legionella species, samples pos-
itive for Legionella were retested at the reference laboratory [13].
Because few whole blood samples from Thailand and 
Bangladesh were positive for lytA PCR, we retested a random 
sample of 100 documented pneumococcal carriers (NP/OP 
specimens positive for S.  pneumoniae) from both sites using 
the PERCH lytA PCR assay at the reference laboratory. No false 
negative blood results were found.
Measles PCR
NP/OP swabs from all 33 cases with clinical signs or history 
of measles were tested for measles virus by PCR using the 
nucleoprotein gene target [14] at the reference laboratory. 
Suspected measles was defined as a history of measles in the 
past 3 months, measles rash at admission, or measles diagnosis 
at admission or discharge.
Organism Identification Antimicrobial Susceptibility Testing
Organism identification was done according to standard micro-
biological methods that were documented in SOPs and clarified 
at each site at the outset; antimicrobial susceptibility testing fol-
lowed the Clinical and Laboratory Standards Institute (CLSI) 
guidelines [15]. Antimicrobial susceptibility was tested using 
overnight growth of pure isolates, using the disk diffusion meth-
odology when possible. Streptococcus pneumoniae isolates that 
had reduced susceptibility to penicillin by the oxacillin screen 
were tested by Etest (bioMérieux, low-dose strips) or a commer-
cially available broth MIC method (TREK Diagnostic Systems) 
to measure minimum inhibitory concentrations (MIC) to peni-
cillin. Enterobacteriaceae were screened for extended spectrum 
β-lactamase production using a cefotaxime (30 µg) disk and a 
ceftazidime (30 µg) disk. Zone sizes ≤27 mm for cefotaxime or 
≤22 mm for ceftazidime were confirmed by the double disk dif-
fusion test, following the CLSI guidelines. Organism identifi-
cation was confirmed for each specimen type and is described 
below. Antibiotic susceptibility testing results were confirmed 
in a sample of 10% of isolates from all sites with 100% concord-
ance of results.
Blood Culture Processing
Blood cultures were incubated per manufacturer instructions 
using automated systems (BACTEC [Becton Dickinson, Sparks, 
Maryland] in Kenya, South Africa, The Gambia, Mali, and 
Zambia; BacT/ALERT [bioMérieux, Marcy l’Etoile, France] 
in Bangladesh and Thailand). Culture bottles were incubated 
within 24 hours of specimen collection. Alarm-positive culture 
specimens were plated on to 5% sheep or horse blood, chocolate, 
and MacConkey agar. Specimens were incubated for 5 days and 
then discarded. Specimens that were alarm-positive but subcul-
ture negative were tested using the BinaxNOW Streptococcus 
pneumoniae Antigen Card (Alere, Scarborough, Maine) if the 
Gram stain was either negative or revealed gram-positive cocci. 
Organisms were identified and antimicrobial susceptibility 
testing was performed according to CLSI methods. Any isolate 
classified as a contaminant was not stored; all other organisms 
were identified then stored at –80°C. Organisms were defined, 
a priori, as contaminants (Table 2). Of 195 stored blood culture 
isolates, 146 (72%) were shipped for confirmatory identification 
at the reference laboratory; of these, 121 (83%) were concord-
ant with the original result. In the absence of strong evidence 
otherwise, organisms meeting the a priori contaminant defini-
tion were considered as contaminants. Candida species was also 
considered a blood culture contaminant if the patient recovered 
without antifungal treatment.
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NP Swab Processing for the Detection of Pneumococcal Carriage
NP swabs in skim milk tryptone-glucose-glycerin (STGG) 
medium were frozen at –80˚C overnight, then thawed and pro-
cessed using a broth-enrichment step to enhance pneumococ-
cal carriage recovery [16, 17]. Streptococcus pneumoniae was 
identified by colony morphology, susceptibility to optochin, 
and bile solubility testing. Samples were inoculated onto 5% 
sheep or horse blood agar with 5 µg of gentamicin per milli-
liter and incubated at 35°C ± 2°C for 18–24 hours. Following 
subculture, each morphologically distinct pneumococcal col-
ony was isolated and stored, with up to a maximum of 4 isolates 
per plate.
Induced Sputum Culture
Efforts were made to process sputum specimens within 2, and 
no more than 24, hours following collection. Gram-stained 
smears were made from the most purulent portion of each 
induced sputum specimen. The number of epithelial cells and 
neutrophils per low-powered microscopic field were counted 
and recorded for the purpose of assessing specimen quality [18]. 
Microorganisms seen in the smear were described according to 
classic Gram stain morphotypes, with the number of bacterial 
morphotypes seen per high-powered field recorded to assist in 
interpretation of culture results.
The most purulent portion of each specimen was inoculated 
onto sheep or horse blood, chocolate, and MacConkey agars, 
streaked out using the 4-quadrant streaking method, and incu-
bated at 35°C for 48 hours. Cultures were examined at 24 hours 
and 48 hours, and predominant organisms were identified and 
quantified according to the furthest quadrant with visible col-
onies (first quadrant  =  scanty; second quadrant  =  1+; third 
quadrant = 2+; fourth quadrant = 3+). Background mixed oro-
pharyngeal flora, including α-hemolytic streptococci, commen-
sal Neisseria, coagulase-negative staphylococci, yeasts (except 
Cryptococcus), diphtheroids, and Capnocytophaga were quanti-
fied as a group but not identified further. Induced sputum spec-
imens were also cultured for mycobacteria by standard liquid 
culture methods.
Pleural Fluid and Lung Aspirate Culture
Gram stains were performed on all pleural fluid and lung aspi-
rate specimens, and the number of leukocytes per low-powered 
field and bacterial morphotypes per high-powered field was 
recorded. Each specimen was cultured by plating onto chocolate 
and MacConkey agar and also inoculated in appropriate broth 
(blood culture bottles, tryptone soy broth, brain heart infusion, 
and brucella broth) and overnight incubation at 35°C–37°C. All 
plated and broth growth was examined at 24 hours and iden-
tified according to standard microbiological methods. Pleural 
fluid supernatant was assayed for protein and glucose and tested 
using the BinaxNOW Streptococcus pneumoniae Antigen Card. 
Pleural fluid and lung aspirate specimens were cultured for the 
presence of mycobacteria in liquid culture. Of 20 available pleu-
ral fluid and lung aspirate isolates, 12 (60%) were shipped to the 
reference laboratory for confirmation and all had their original 
organism identification confirmed.
Pneumococcal Serotyping
Pneumococcal capsular serotyping was performed by the 
following methods: Quellung reaction (Zambia, South 
Table 2. Predefined Blood Culture Contaminants
Contaminant Organisma
Aerococcus viridans
Streptococcus, α-hemolytic (viridans)
Bacillus species
Bacillus subtilis
Corynebacterium amycolatum
Corynebacterium kroppenstedtii
Corynebacterium macginleyi
Corynebacterium minutissimum
Corynebacterium species
Corynebacterium striatum
Corynebacterium ureolyticum
Corynebacterium pseudodiphtheriticum
Corynebacterium xerosis
Lactobacillus species
Leuconostoc species
Micrococcus species
Propionibacterium acnes
Propionibacterium avidum
Propionibacterium species
Staphylococcus capitis
Staphylococcus cohnii
Streptococcus constellatus
Staphylococcus epidermidis
Streptococcus gordonii
Staphylococcus hominis
Streptococcus intermedius
Staphylococcus kloosii
Streptococcus mitis
Staphylococcus muscae
Streptococcus mutans
Streptococcus oralis
Streptococcus parasanguis
Streptococcus salivarius
Streptococcus sanguinis (sanguis)
Staphylococcus sciuri
Staphylococcus simulans
Staphylococcus, coagulase-negative
Staphylococcus haemolyticus
Staphylococcus intermedius
Staphylococcus schleiferi
Staphylococcus warneri
Staphylococcus xylosus
aAll other organisms identified by blood culture were reviewed on a case-by-case basis to 
determine whether they were likely to be contaminants or the likely cause of the current 
hospitalization.
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Africa), PCR deduction of pneumococcal serotypes [19] 
followed by Quellung reaction if there were mixed or 
ambiguous results by PCR (Thailand, Mali, The Gambia, 
Bangladesh), or latex agglutination at pool level with 
Quellung reaction for final typing and PCR confirmation of 
a subset of isolates as a quality control procedure (Kenya). 
Mixed or ambiguous results that could not be resolved at 
the study sites were serotyped by Quellung reaction at a 
reference laboratory (National Institute for Communicable 
Diseases, Johannesburg, South Africa or the Institute of 
Environmental Science and Research [ESR], Porirua, New 
Zealand). Serotyping for all pneumococcal isolates isolated 
from sterile sites as well as a sample of 50–75 pneumococcal 
isolates from the NP swab culture was verified by Quellung 
at the ESR laboratory.
Haemophilus Serotyping
Haemophilus influenzae were identified at all sites using stand-
ard microbiological methods; serotype b was identified by slide 
agglutination. Additional (non type b) serotyping was per-
formed in South Africa and The Gambia by slide agglutination. 
For all other sites, serotyping beyond type b was done by PCR 
at the reference laboratory (Canterbury Health Laboratories, 
Christchurch, New Zealand) [20].
Antibiotic Bioassay
A bioassay was performed on enrollment serum samples, from 
all cases and controls, to detect antibiotic activity. A 6-mm filter 
paper disc was inoculated with 20 µL of serum and placed on a 
Mueller-Hinton plate seeded with a 0.5 McFarland suspension 
of a fully sensitive Staphylococcus aureus strain (ATCC 25923). 
Any zone of inhibited bacterial growth around the disc after 
18–24 hours’ incubation was recorded as evidence of serum 
antibiotic activity.
C-Reactive Protein
Serum from all cases was assayed for C-reactive protein 
(CRP). Samples from South Africa were assayed in coun-
try using CRP Gen3 Immunoturbidometric assay (Roche 
Diagnostics, Milan, Italy). All other samples were assayed 
at the reference laboratory in Christchurch, New Zealand, 
using CRP VARIO Immunoturbidometric assay (Roche 
Diagnostics). A subset of 682 control samples was assayed 
for CRP as part of an analysis to evaluate its diagnostic 
utility [21].
LABORATORY INVESTIGATIONS DONE ACCORDING 
TO LOCAL PROTOCOL
Other Blood Tests
A complete blood count was performed on all cases. Hemoglobin 
testing for controls was also carried out in The Gambia, Mali, 
and South Africa. Thalassemia testing for cases and controls 
was done in Thailand.
Mycobacterial Culture
Culture of induced sputum and gastric aspirate specimens for 
mycobacteria was performed using liquid media in established 
tuberculosis testing laboratories at all sites. Antimicrobial sus-
ceptibility testing was performed on all Mycobacterium tuber-
culosis isolates. Isolates of nontuberculous mycobacteria were 
identified at the reference laboratory by 16S ribosomal RNA 
and rpoB sequencing [22–24].
Malaria Testing
Malaria testing was performed by rapid antigen test or micros-
copy for all cases at sites with endemic malaria (Kenya, The 
Gambia, Mali, Zambia) and in South Africa when clinically 
indicated.
Human Immunodeficiency Virus and CD4 Testing
Human immunodeficiency virus (HIV) testing was done on all 
cases at all sites apart from Bangladesh, and for controls at all 
Africa sites with the exception of The Gambia (which has an 
HIV infection prevalence of <2%). Testing was done by serum 
antibody assay, followed by PCR confirmatory antigen testing 
for cases and controls <18 months of age. In Zambia and South 
Africa, CD4 assessments were performed or collected from 
referral facilities for all HIV-infected cases and controls.
Pneumocystis Testing
All respiratory specimens were tested for P. jirovecii nucleic acid 
by Fast-track PCR. Additionally, induced sputum, endotracheal 
aspirate, pleural fluid, and lung aspirate specimens were tested 
for P. jirovecii by immunofluorescence (South Africa) and tolu-
idine blue staining (Zambia).
INITIAL STANDARDIZATION AND TRAINING
Laboratory SOPs were developed in collaboration with site 
investigators for all core laboratory procedures. All sites under-
went a period of training and pilot testing prior to study initia-
tion. Following demonstration of successful performance, a site 
activation letter allowed formal study enrollment to commence 
[8]. The PERCH laboratory director, in conjunction with other 
team members, visited and evaluated each study laboratory 
prior to study piloting and provided advice on areas for addi-
tional improvement of facilities or training of staff.
Major equipment, including the nucleic extraction platform 
and PCR thermocyclers, was procured centrally and installed 
at each site laboratory. In addition, maintenance contracts were 
provided for the period of the study. Training on the nucleic acid 
extraction system was provided by bioMérieux at installation. 
Fast-track PCR training was provided in-person by Fast-track 
Diagnostics over a period of 3 days at each site. Trained staff 
received a certificate of completion and the site laboratory was 
required to pass an external quality assurance assessment before 
beginning molecular diagnostic testing on study samples.
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Sites were trained on induced sputum slide reading at an ini-
tial training and again at a midstudy refresher training. A subset 
of approximately 10% of slides from each site were stored fol-
lowing reading and later sent to the reference laboratory where 
they were audited. Sites that were unable to send slides had a 
random sample checked by the laboratory director during study 
oversight visits.
Key SOPs were reviewed with laboratory scientists from 
all sites at an investigator meeting prior to study initiation, 
Training on the data capture system and freezer inventory soft-
ware was provided remotely via a webinar prior to the start of 
the study.
Ongoing Standardization and Quality Assurance
A working group including the laboratory director and repre-
sentatives from all site laboratories was convened throughout 
the study to harmonize practices and troubleshoot problems at 
periodic investigator meetings and through regular teleconfer-
ences. A midstudy in-person refresher training on core labora-
tory procedures was conducted for all sites in August 2012. The 
laboratory director visited each study site at least twice over the 
course of the study to provide on-site monitoring. Laboratory 
quality indicators were monitored using the real-time data entry 
system and were used to identify areas for improvement over the 
duration the study [8]. Electronic laboratory data reports were 
generated from the database and reviewed at regular intervals 
by the laboratory director. In addition, digital PCR results files 
were rechecked at the reference laboratory to confirm accurate 
interpretation of PCR quantification curves. Discordant inter-
pretations of results were discussed with the laboratories and 
corrected in the database.
External Quality Control Assessments
An external quality assessment (EQA) program was set up by 
Fast-track Diagnostics to monitor performance of the Fast-
track respiratory PCR and whole blood lytA PCR assays at each 
site. For the Fast-track respiratory EQA, laboratories were sup-
plied with a series of 12 samples containing mixtures of plas-
mids at various concentrations at 3- to 4-month intervals. Each 
laboratory was required to test the samples using its routine 
FTD Resp-33 assay and standard procedures. Panels for the 
whole blood lytA PCR EQA were dispatched from FTD at the 
same frequency and included blinded plasmid samples contain-
ing the lytA target in a range of concentrations. For each round 
of EQA, an individual performance report was provided along 
with details of overall performance for all sites. Reports and 
practical feedback allowed participants to identify and resolve 
potential problems whilst monitoring the effectiveness of their 
laboratory quality assurance processes. Site-to-site variation 
was also assessed using these reports.
All sites were enrolled in an EQA program for the microbi-
ological assessment of respiratory specimens, organized by the 
Royal College of Pathologists of Australasia Quality Assurance 
Programme. EQA panels were dispatched on a quarterly basis 
and consisted of simulated clinical specimens for the isolation 
of pathogens, bacterial identification and antimicrobial suscep-
tibility testing. Most module shipments consisted of 2 speci-
mens containing either a pure culture or a mixture simulating 
a clinical specimen with normal body flora. Following each 
dispatch, results were reviewed by the laboratory director and 
discussed with the site laboratories.
DISCUSSION
We faced challenges in applying such a high level of standard-
ization to a complex study across diverse research sites. Sites 
varied considerably in their prior level of experience with the 
PERCH laboratory methods and therefore required varying 
levels of assistance and oversight. Assuring that each labora-
tory had standard equipment in place and was comprehensively 
trained meant that the initiation of study enrollment and full 
specimen testing was delayed by weeks to months in some 
instances. Maintaining a high level of involvement and in-per-
son oversight required regular travel by the laboratory director 
in addition to frequent communication by phone and email. 
Additionally, local approvals to ship specimens and isolates for 
confirmatory testing resulted in long delays in the reference 
laboratory receiving samples from some sites. Despite these 
challenges, we were able to achieve the highest methodological 
standards across a variety of circumstances, and demonstrated 
the ability to set up very complex molecular diagnostics in chal-
lenging environments. Achieving standards was a very positive 
motivator among laboratory staff, especially in laboratories 
that had not used international standards before. The value 
of regular feedback to the staff was evident in our study and 
we observed laboratory capacity and technical skills improve 
rapidly over a short period of time, with some of the labora-
tories without prior similar experience becoming the highest 
performers. Applying a high level of standardization required 
considerable effort in the study planning stage and throughout 
the enrollment and testing period, but in the end this effort was 
outweighed by our confidence that results were accurate and 
comparable across sites.
CONCLUSIONS
PERCH was one of the largest pneumonia etiology studies ever 
undertaken, with a complex testing algorithm applied to >9500 
individuals distributed over 9 enrollment centers in 7 different 
countries. Considerable efforts were made to perform as much of 
the laboratory testing at the study sites as possible, and to ensure 
cross-site standardization of testing methods. As well as provid-
ing confidence in the PERCH analyses, our experiences provide 
evidence that multisite studies involving extensive laboratory 
assessments and including complex molecular diagnostics can be 
Downloaded from https://academic.oup.com/cid/article-abstract/64/suppl_3/S245/3858214
by London School of Hygiene & Tropical Medicine user
on 26 January 2018
S252 • CID 2017:64 (Suppl 3) • Driscoll et al
undertaken at research sites in a variety of settings and circum-
stances, including those with limited prior experience.
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Consisting of data provided by the authors to benefit the reader, the posted 
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